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Background: Women seem to experience lower efficacy and safety of atrial fibrillation (AF) ablation. 
Methods: We assessed first AF ablation outcomes on continuous anticoagulation in 633 patients (209 
[33%] women and 424 [67%] men) in a pre-specified subgroup analysis of the AXAFA-AFNET 5 trial. 
We compared the primary outcome (death, stroke or TIA, or major bleeding) and secondary outcomes 
(change in quality of life (QoL) and cognitive function) 3 months after ablation.  
Results: Women were older (66 vs. 63 years, P<0.001), more often symptomatic, had lower QoL and 
a longer history of AF. No sex differences in ablation procedure were found. Women stayed in hospital 
longer than men (2.1±2.3 vs. 1.6±1.3 days, P=0.004). The primary outcome occurred in 19 (9.1%) 
women and 26 (6.1%) men, P=0.19. Women experienced more bleeding events requiring medical 
attention (5.7% vs. 2.1%, P=0.03), while rates of tamponade (1.0% vs 1.2%) or intracranial 
haemorrhage (0.5% vs. 0%) did not differ. Improvement in QoL after ablation was similar between the 
sexes (SF-12 physical 5.1% and 5.9%, P=0.26; and SF-12 mental 3.7% and 1.6%, P=0.17). At baseline, 
(mild) cognitive impairment according to the Montreal Cognitive Assessment was present in 65 (32%) 
women and 123 (30%) men and declined to 23% for both sexes at end of follow-up.  
Conclusion: Women and men experience similar improvement in QoL and the Montreal Cognitive 
Assessment after AF ablation on continuous anticoagulation. Longer hospital stay, a trend towards more 













Catheter ablation has become a routine procedure in patients with atrial fibrillation (AF) to improve 
symptoms and quality of life by reducing the arrhythmia burden. Since women experience more AF 
related symptoms than men, and report a lower quality in AF, they have potentially the most to gain 
from a successful ablation.(1) However, women are less likely to receive catheter ablation, and in the 
last ten years the proportion of women undergoing AF ablation has not increased in the similar manner 
as in men.(2-4) Compared to men, women who undergo AF ablation are generally 4-6 years older, seem 
to experience more AF recurrences, and appear to be at greater risk of having ablation related 
complications.(2,3,5) In several clinical scoring systems including procedural failure(6) or procedure 
related complications(7), female sex is one of the predictors, and in particular vascular injury or cardiac 
tamponade after catheter ablation seem to occur more often in women.(8) However, several other long-
term observational studies found no sex difference in outcome or complications after ablation, 
suggesting selection bias in earlier cohorts.(9,10) Further, female sex was not found to be a predictor 
of AF recurrence in any of the 23 studies included in a systematic review of AF recurrence predictors 
after ablation.(11) Little is known about the safety of AF ablation on continuous anticoagulation with 
regard to sex.  
There is a lack of sex-specific analyses of large, prospective, contemporary AF ablation data sets with 
well-structured patient-, procedure-, and outcome variables. We set out to study sex-related differences 
in catheter ablation procedure, outcome, quality of life, and cognitive function in a predefined substudy 
of all patients included in The Anticoagulation using the direct factor Xa inhibitor apixaban during 









The AXAFA-AFNET 5 study was a prospective, multi-centre, 1:1 randomized, blinded outcome 
assessment study that compared continuous therapy of the non-vitamin K antagonist (NOAC) apixaban 
therapy to vitamin K antagonist (VKA) therapy in patients undergoing first AF ablation. All patients 
had symptomatic non-valvular AF, a clinical indication for catheter ablation on continuous 
anticoagulant therapy, and at least one established stroke risk factor (age ≥75 years, symptomatic heart 
failure, hypertension, diabetes mellitus or prior stroke or transient ischemic attack). Full inclusion and 
exclusion criteria of the AXAFA-AFNET 5 trial have been previously published.(12) 
Patients randomized to apixaban received 5 mg twice daily, which was continued during the ablation 
procedure without interruption. Dose adjustment occurred if two or more of the following patient 
characteristics were present: age ≥80 years, weight ≤ 60kg, or serum creatinine level ≥1.5mg/dL (133 
µmol/L). Patients randomized to VKA were treated according to site specific anticoagulation therapy 
routine (warfarin, phenprocoumon, or acenocoumarol). Patients could undergo ablation after at least 30 
days of continuous anticoagulation which was defined as having taken all but one dose, based on pill 
count, in the apixaban group and at least 3 INR measurements prior to ablation, with the last INR before 
ablation being ≥1.8, in patients receiving VKA therapy. Ablation could be performed earlier if atrial 
thrombi were excluded by transoesopagheal echocardiography and patients had at least 2 adjacent 
apixaban doses, or an INR ≥1.8, before ablation. The ablation procedure followed current guidelines, 
could be either radiofrequency ablation or cryoballoon ablation, and was conducted according to local 
practice. Throughout the ablation procedure an activated clotting time (ACT) >300s was targeted. 
Directly after ablation a mandatory echocardiogram was performed to detect pericardial effusion.  
The trial was conducted in 48 sites in Europe and North America, and sponsored by AFNET 
(www.kompetenznetz-vorhofflimmern.de) All adverse events were adjudicated by an independent 
endpoint review committee blinded to study group and INR values. The study was conducted in 
accordance with the declaration of Helsinki and the International Conference on Harmonization Good 
Clinical Practice Guidelines (ICH-GCP). The ethical review board of all study centres approved the 




The analysis population included all patients from the AXAFA trial population who were randomized 
and underwent catheter ablation (i.e., modified intention-to-treat [mITT] population, Figure 1). 
 
Study outcomes and measures 
Primary outcome was the composite of all-cause death, stroke or TIA, or major bleeding (defined as 
Bleeding Academic Research Consortium score (13), developed to capture peri-interventional bleeding 
complications [BARC] ≥2) measured from randomization until the 3-month follow-up visit. Pre-
specified secondary outcomes of the AXAFA-AFNET 5 trial included changes in quality of life, 
cognitive function, prevalence and number of MRI-detected acute brain lesions, and nights spent in 
hospital after the index ablation.  
At baseline patient characteristics, symptoms (assessed using the modified European Heart Rhythm 
Association (mEHRA) score), quality of life (assessed using the 12-item Short Form Health Survey 
(SF-12), the Karnofsky Performance Status Scale, and Euro-QoL 5-Dimensional questionnaire (EQ-
5D)) and cognitive function (assessed by the Montreal Cognitive Assessment Test (MoCA) test were 
collected. The SF-12 survey consists of multiple choice questions that range in a stepwise fashion from 
limited a lot/all the time to not limited at all/none of the time. The individual items are transformed to 
a physical and mental health score ranging from 0-100, with lower scores representing a lower quality 
of life. The Karnofsky scale (ranging from 0-100) describes global function status with scores from 0-
40 implying inability to care for self; 50-70 inability to work, varying amount of assistance needed; and 
80-100 ability to carry on normal activity and to work. The EQ-5D score rates mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression on a 3-level scale ranging from no problems to severe 
problems. The final index score, using the UK value set ranges from 0-1, with lower scores representing 
a lower quality of lfe. The MoCA test contains items on orientation, attention, verbal memory, language, 
visuospatial function, and executive function. Scores range from 0 to 30, with a score of ≥26 being 
considered normal.(12)  
Follow up visits took place at the time of ablation and after 3-months. At the 3-month visit quality of 
life, and MoCA scores were reassessed. Additionally, a 12 lead ECG and 24 hour Holter was performed 
to detect AF recurrence after the blanking period as per consensus definition. Data on hospitalizations 
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and nights spend in hospital after index ablation was collected.  A subset of patients received a brain 




Descriptive statistics for continuous and categorical variables were summarized as means (SDs) and 
medians (25th [q1], 75th [q3] percentiles), and counts (percentages), respectively. Comparisons between 
continuous variables were performed using the Wilcoxon rank-sum test or two-sample t-test depending 
on normality; comparisons between nominal variables were performed using the Pearson’s χ2 test or 
Fisher’s exact test, depending on expected cell sizes. Changes in quality of life (SF-12, Karnofsky scale, 
and EQ-5D,) and MoCA scores from baseline to 3 months’ post index ablation were assessed. Paired 
measurements in women and men were compared with the Wilcoxon matched pairs signed rank. The 
amount of quality of life change between the sexes was compared with the Wilcoxon rank-sum test. A 
multivariable Cox proportional hazards model, controlling for the baseline risk factors of age, weight, 
type of AF, CHADS2VAS2c-score, and randomization arm was conducted to assess differences in 
primary endpoint occurrence between the sexes. The Cox proportional hazards assumption was assessed 
by visually inspecting plots of Schoenfeld residuals against time, which showed no proportionality 
violation. Some variables had missing data; in case of incomplete data the number of patients with 
available data is added to the tables. All analyses were two-sided and tested at the nominal 0.05 
significance level. No adjustments were made for multiple comparisons. All statistical analyses were 
performed with IBM SPSS Statistics version 24 (IBM Corp., Armonk, NY, USA) 
 
Results 
Patient characteristics and AF complaints 
From the 674 patients who were randomized in the AXAFA-AFNET 5 study, 633 patients underwent 
catheter ablation, forming the modified intention-to-treat (mITT) population (Figure 1). Women (n=209 
[33%]) were older (66 vs. 63 years, P<0.001) and consequently had a higher CHA2DS2-VASc score 
(3.2±1.1 vs. 2.1±1.1, p<0.001) compared to men (n=424 [67%]) (Table 1). Other comorbidities were 
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well balanced between the sexes, with the exception of coronary artery disease that was more often 
present in men (5.3% vs. 15.6%, P<0.001). The average number of risk factors was 2.9±1.1 in women 
and men. Women more often had paroxysmal AF (64% vs. 55%), with a higher frequency of AF 
episodes, and more often experienced their first occurrence of AF symptoms >12 months before 
ablation (75% vs. 63%). The modified EHRA score (IIb-IV) was higher in women than in men (Table 
1). No relevant differences in concomitant medication use were observed. 
 
Index catheter ablation 
Median time from randomization to ablation was similar in women and men (36 and 35 days, 
respectively). Heart rhythm at the start of ablation, type of ablation, ablation energy source, and 
procedure time did also not differ between the sexes (Table 2). Women and men received comparable 
continuous anticoagulation. Women stayed longer in hospital after ablation than men (2.1±2.3 vs. 
1.6±1.3 days, P=0.004).  
 
Primary outcome 
The primary outcome (all-cause death, stroke or TIA, or BARC 2-5 bleeding) was observed in 19 (9.1%) 
women and 26 (6.1%) men, P=0.19 (Table 3), with an adjusted hazard ratio of 1.5 (95% CI 0.75 – 3.0; 
P=0.25) for the primary endpoint in women compared to men (Figure 2). Vascular access complications 
requiring therapy did not differ between sexes, but BARC 2 bleeding events occurred more often in 
women than in men (5.7% vs. 2.1%). Other bleeding events, including TIMI (1.0% vs. 0.5%) and ISTH 
(5.3% vs. 3.1%) major bleeding, cardiac tamponade (1.0% vs. 1.2%), death (0.5% vs. 0.2%) or stroke 
or TIA (0% vs. 0.5%) occurrence did not differ between the sexes (Table 3).  
AF recurrence rate was not significantly different between women and men (34% vs. 28%, P=0.09). 
Similarly, there was no cardiovascular hospitalization difference (25.4% vs. 19.6%, P=0.10). Both 
women and men spend a median of 3 nights in hospital during follow-up (Table 3).  
 
Secondary outcomes 
Quality of life 
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Baseline quality of life was lower in women than in men (Table 4). This was true for the SF-12 physical 
component, the SF-12 mental component, the Karnofsky scale, and the EQ-5D score.  In women and 
men, the SF-12 physical (5.1% vs. 5.9%) and mental (3.7% vs. 1.6%) component scores increased and 
the Karnofsky scale remained stable or improved (both interquartile range 0 – 12.5%) during follow-
up. The amount of improvement did not differ statistically between the sexes. The EQ-5D score did not 
improve in women, contrary to men. At the end of follow up women continued to have a lower quality 
of life with lower SF-12 physical, SF-12 mental and EQ-5D scores.  
 
Cognitive function and acute brain lesions 
Baseline MoCA scores were similar in women and men, with a median of 27 points (Table 5). At the 
end of follow-up, MoCA increased by a median of 1 point (ranging from -1 to 2 points) in women and 
0 (ranging from-1 to 2 points) in men, P=0.37. At least mild cognitive impairment according to the 
MoCA score was observed in 65 (32%) women and 123 (30%) men at baseline, this reduced to 23% 
for both sexes at end of follow-up. 323 patients had analysable MRIs. Acute brain lesions were detected 















In this contemporary cohort of patients undergoing AF ablation on continuous anticoagulation, women 
were older than men, more often symptomatic, and with lower quality of life at baseline. There was no 
difference between women and men in primary outcomes after AF ablation with a similar rate of adverse 
events, with the exception of a trend towards more nuisance (BARC 2) bleedings and a longer time 
spent in hospital for the procedure. Quality of life and MoCA test results improved in a similar fashion 
in both sexes, although overall quality of life remained lower in women than in men.  
 
Patient population 
Catheter ablation is a mainstay in the treatment of AF, but currently most patients receiving an ablation 
for AF are white men. Registry studies as well as randomized controlled trials show an 
underrepresentation of women, with only ~20-40% females.(2-4) This may represent under-treatment 
of women, who besides more AF-related symptoms are also less likely to successfully respond to 
pharmacological treatment and more often fail antiarrhythmic medication than men before receiving 
catheter ablation.(1) Women who do receive an ablation tend to be older, have a longer duration of the 
arrhythmia, and more comorbidities including hypertension and valvular disease.(5,10) The lower 
success rate of catheter ablation in women, as well as the higher complication rate, may be partially 
related to these high risk features.(1) Women included in AXAFA-AFNET 5 had a longer history of 
AF and were on average 3 years older, but had a largely similar underlying risk factor burden. In the 
randomized FIRE AND ICE trial, and the German Ablation Registry women were on average 5 to 7 
years older, and had worse kidney function (FIRE AND ICE), and more often hypertensive heart disease 
(German Ablation Registry).(3,4) Both these studies describe distinct sex-related outcomes in contrast 
to our observations. Whether observed sex-differences are solely a reflection of older age with more 
risk factors in women, or dependent on sex-differences in anatomy, physiological- and 
pathophysiological mechanisms, remains incompletely understood.(1) 
Catheter ablation procedure 
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No significant differences were observed in index catheter ablation procedure itself. The only difference 
was the observation that women had a prolonged hospital stay after index ablation of ~0.5 day, an 
observation also reported in the FIRE AND ICE trial.(4) Reasons remain elusive, but may include more 
(atypical) symptoms after catheter ablation, in line with women’s higher symptom burden in general, 
or caution of the treating physician who may expect a more complicated course of the ablation 
procedure in women.(1)  
 
Outcomes 
BARC 2 type bleeding (bleeding events that required medical attention)(13) occurred slightly more 
often in women. Vascular access complications that resulted in actual prolongation of in-hospital stay 
or specific therapy such as surgery or supplementation of coagulant factors were extremely rare and 
occurred in only two women and one man. Most studies describe a higher prevalence of nonfatal access 
complications in women.(2,3,6) Reasons may include the older age at the time of ablation, sex-specific 
anatomical varieties of the groin vessels, or obesity, an associated risk factor for more complications.(1) 
Almost all women included in AXAFA had BMIs within the 25-30 kg/m2 range, however, the same 
was true for the men. Bleeding events requiring invasive treatment beyond medical attention (e.g. 
surgery or transfusion) did not differ between the sexes. Importantly, cardiac tamponade did not occur 
more often in women. In AXAFA-AFNET 5 the ablation approach was similar between the sexes, i.e. 
women did not receive more extensive ablations with additional ablation lines. Also, per protocol, ACT 
was closely monitored and targeted >300 ms during the ablation, which may have contributed to 
improved procedural safety. Furthermore, included sites in the AXAFA-AFNET 5 study had 
experienced personnel. The influence of poorer outcomes in low-volume centres might have therefore 
been prevented.(8) Short-term AF recurrence did not differ between the sexes. Similar early success in 
both women and men was also observed in the FIRE AND ICE trial.(4) Long-term efficacy, which was 
not studied in AXAFA-AFNET 5, is often lower in women and is heavily influenced by a longer history 




Quality of life  
Quality of life was lower in women at baseline, and remained lower at follow-up. This lower quality of 
life in women was frequently observed and reflects more symptoms, a reduced capacity to carry on 
normal activity and work, and is associated with more concerns regarding treatment approaches.(15) 
However, with the exception of the EQ-5D score, the improvement in quality of life was similar, 
implying that benefits of ablation are largely the same in women in men, making it a more promising 
strategy than anti-arrhythmic drugs alone in improving patient’s life.(16,17) Advancing age is 
associated with more concerns and anxiety regarding personal health, and a negative impact on overall 
health status status.(16,17) The lack of improvement in the EQ-5D score may reflect the higher median 
age of women in our cohort. Incorporation of health-related questionnaires may show which patients 
could potentially benefit the most from catheter ablation, and may be used as a means of minimizing 
sex-differences in management strategies.(15)  
 
Cognitive function and MRI-detected acute brain lesions 
AF is associated with a ~1-3 fold increased risk of cognitive impairment and dementia.(18) Especially 
vascular risk factors, including diabetes mellitus and stroke, are strongly associated with cognitive 
impairment and a higher prevalence of dementia.(18) To our knowledge no clear sex-specific 
differences in the relationship between cognition and sex in patients with AF have been observed so 
far. In AXAFA-AFNET 5, MoCA scores were similar in women and men. The number of study patients 
with acute brain lesions after ablation (~25%) was in line with previous publications (19,20) and without 
significant differences in women and men. In light of this relatively high percentage of acute brains 
lesions, the observation that in both women and men the presence of at least mild cognitive dysfunction 
according to the MocA test decreased in a similar manner from 32% and 30%, respectively to 23% at 





The current study supplies evidence that catheter ablation provides uniform benefit to women and men 
in terms of effectiveness in maintaining short-term sinus rhythm increase in QoL and cognitive function 
as assessed by the MoCA test. Importantly, no major differences regarding safety were observed. With 
the exception of slightly more nonfatal bleeding BARC 2 bleeding events, no differences in tamponade 
occurrence or vascular injury requiring transfusion were observed. Evolving ablation techniques, 
intracardiac echocardiography and ultrasound guidance may in the future further reduce complications 
and completely eliminate any difference in complication rates between women and men. Increase in 
quality of life is one of the key reasons to perform ablation. The fact that women can achieve similar 
results as men is an important reason not to withhold this therapy from women. The barriers, as well as 
facilitators, of catheter ablation in women deserve more attention as offering catheter ablation to more 
women holds an opportunity to positively affect outcomes. 
 
Study limitations 
Although, this was a pre-specified analysis of AXAFA-AFNET 5, the study was not powered to detect 
sex differences. While patient characteristics, anticoagulation treatment, and ablation procedure did not 
show large differences between women and men, unmeasured confounders may be unbalanced. 
Prevalence of certain outcome events, including death and stroke or cardiac tamponade, was low which 
may have limited power to detect sex-differences. Data on incidence of esophageal thermal lesions was 
missing. Additionally, changes in QoL and cognitive function were analyzed at 3-months and therefore 
reflect short-term outcomes that prohibit making valid conclusions about the long-term effects of AF 
catheter ablation on these parameters.  
Conclusion 
The current AXAFA-AFNET 5 analysis revealed no major sex-differences in terms of efficacy and 
safety of first-time catheter ablation under continuous anticoagulation. The increase in QoL and 
improvement in MoCA test score during follow up was largely similar for women and men. Therefore, 
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considering that hospital stay may be slightly longer in women than in men, ablation should not be 
withheld from women with symptomatic AF. 
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Figure legends 
 
Figure 1. Flowchart  
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Flowchart of the AXAFA-AFNET 5 study. The current analysis focused on the patients who underwent 




Figure 2.  Cumulative Primary Outcome Occurrence 
Shows the cumulative occurrence of primary outcome events from randomization until 90 days follow up. 



























Table 1. Baseline characteristics ablation population 







Clinical characteristics*     
Age –  years  64 (58, 70) 66 (60, 72) 63 (57, 69) <0.001 
Height – cm  175 (168, 182) 165 (161, 170) 180 (174, 185) <0.001 
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Weight – kg  87 (77, 99) 77 (68, 90) 90 (82, 103) <0.001 
Body mass index – mg/kg2  28.3 (25.3, 31.6) 28.0 (24.9, 32.7) 28.4 (25.4, 31.2) 0.81 
Systolic blood pressure – mmHg  138 (125, 150) 140 (127, 152) 137 (124, 150) 0.15 
Diastolic blood pressure – mmHg  82 (76, 90) 83 (74, 90) 82 (76, 90) 0.884 
CHA2DS2-VASc score   2 (2, 3) 3 (2, 4) 2 (1, 3) <0.001 
CHA2DS2-VASc score  - mean 
(SD) 
2.4 (1.2) 3.2 (1.1) 2.1 (1.1) <0.001 
Randomization – n (%)    0.45 
Apixaban† 318 (50.2) 100 (47.8) 218 (51.4)  
VKA 315 (49.8) 109 (52.2) 206 (48.6)  
Medical history – n (%)     
Hypertension 571 (90.2) 186 (89.0) 385 (90.8) 0.48 
Diabetes mellitus 76 (12.0) 22 (10.5) 54 (12.7) 0.52 
Chronic obstructive lung disease 39 (6.2) 12 (5.7) 27 (6.4) 0.86 
Prior stroke or TIA 47 (7.4) 16 (7.7) 31 (7.3) 0.87 
Clinical history of major bleeding 13 (2.1) 4 (1.9) 9 (2.1) 0.99 
Coronary artery disease (history of 
myocardial infarction, percutaneous 
coronary intervention,  or coronary 
artery bypass graft) 
77 (12.2) 11 (5.3) 66 (15.6) <0.001 
Vascular disease (coronary artery 
disease, peripheral artery disease or 
carotid disease) 
83 (13.1) 13 (6.2) 70 (16.5) <0.001 
Heart failure 212 (33.5) 74 (35.4) 138 (32.5) 0.48 
NYHA I 62 (9.8) 15 (7.2) 47 (11.1)  
NYHA II 126 (19.9) 50 (23.9) 76 (17.9)  
NYHA III 24 (3.8) 9 (4.3) 15 (3.5)  
NYHA IV 0 0 0  
Symptomatic (NYHA II-III) 150 (23.7) 59 (28.2) 91 (21.5) 0.07 
Valvular heart disease 73 (11.5) 22 (10.5) 51 (12.0) 0.69 
Mitral valve disease‡  20 (3.2) 6 (2.9) 14 (3.3)  
Aortic valve disease‡ 6 (0.9) 1 (0.5) 5 (1.2)  
No. of risk factors°     
Median (q1, q3) 3 (2-4) 3 (2-4) 3 (2-4) 0.76 
Mean (SD) 2.9 (1.1) 2.9 (1.1) 2.9 (1.1) 0.52 
Rhythm and complaints – n (%)     
AF pattern    0.03 
Paroxysmal  367 (58.0) 134 (64.1) 233 (55.0)  
Persistent or long-standing 
persist 
266 (42.0) 75 (35.9) 191 (45.0)  
Frequency of AF#     0.01 
Occasional 128/593 (21.6) 34/203 (16.7) 94/390 (24.1)  
Intermediate 307/593 (51.8) 109/203 (53.7) 198/390 (50.8)  
Frequent 158/593 (26.6) 60/203 (29.6) 98/390 (25.1)  
First occurrence of AF symptoms    0.003 
No symptoms in the past 40 (6.3) 6 (2.9) 34 (8.0)  
<12 months ago 169 (26.7) 46 (22.0) 123 (29.0)  
>12 months ago 424 (67.0) 157 (75.1) 267 (63.0)  
Modified EHRA scale    <0.001 
mEHRA I 40 (6.3) 6 (2.9) 34 (8.0)  
mEHRA IIa 164 (25.9) 33 (15.8) 131 (30.9)  
mEHRA IIb 205 (32.4) 76 (36.4) 129 (30.4)  
mEHRA III 208 (32.9) 84 (40.2) 124 (29.2)  
mEHRA IV 16 (2.5) 10 (4.8) 6 (1.4)  
Concomitant medications – n (%)     
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Class Ia/Ic antiarrhythmics: 
flecainide, propafenone or 
quinidine 
143 (22.6) 48 (23.0) 95 (22.4) 0.92 
Class III antiarrhythmics: 
amiodarone, dronedarone or sotalol  
132 (20.9) 41 (19.6) 91 (21.5) 0.68 
Beta blockers 451 (71.2) 144 (68.9) 307 (72.4) 0.40 
ACE inhibitor or angiotensin 
receptor blocker 
388 (61.3) 119 (56.9) 269 (63.4) 0.12 
Calcium channel antagonists 147 (23.2) 43 (20.6) 104 (24.5) 0.32 
Diuretics 221 (34.9) 79 (37.8) 142 (33.5) 0.29 
Antianginal medication 2 (0.3) 0 2 (0.5) 0.99 
Antidiabetic medications 63 (10.0) 16 (7.7) 47 (11.1) 0.21 
Statins 231 (36.5) 65 (31.1) 166 (39.2) 0.053 
*Values depicted as median (q1, q3) unless stated otherwise 
† One woman received 2.5 mg twice daily., all other patients received 5 mg twice daily.  
‡ Defined as at least moderate (grade II through IV) 
# Number of patients with available information is given since some patients had missing values 
° Includes advanced age (≥65 years), overweight or obesity (BMI >25), vascular disease, previous stroke or 
TIA, hypertension, diabetes mellitus, chronic obstructive lung disease, heart failure, and at least moderate mitral 
insufficiency. 
ACE, angiotensin converting enzyme; AF, atrial fibrillation; EHRA, European Heart Rhythm Association; 


















Table 2. Index ablation procedure information 







Days from randomization to ablation      
mean (SD) 38.0 (27.3) 37.6 (29.2) 38.2 (26.4) 0.78 
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median (q1, q3) 35 (20, 50) 36 (14, 53) 35 (22, 50) 0.57 
INR prior to ablation  in patients receiving 
VKA - mean (SD) 
2.2 (0.5) 2.1 (0.3) 2.2 (0.6) 0.28 
All, or all but one, dose of apixaban before 
ablation in patients receiving apixaban – n 
(%) 
307/318 (97) 98/100 (98) 209/218 (96) 0.52 
TEE prior to ablation – n (%) 549 (86.7) 181 (86.6) 368 (86.8) 0.99 
Abnormal blood parameters – n (%)*     
Red blood cell count  65/618 (10.5) 26/206 (12.6) 39/412 (9.5) 0.27 
White blood cell count  50/622 (8.0) 15/206 (7.3) 35/416 (8.4) 0.82 
Platelet count  35/625 (5.6) 8/207 (3.9) 27/418 (6.5) 0.37 
ALT  75/612 (12.3) 29/202 (14.4) 46/410 (11.2) 0.54 
AST 59/582 (10.1) 26/195 (13.3) 33/387 (8.5) 0.13 
Bilirubin 38/595 (6.4) 6/193 (3.1) 32/402 (8.0) 0.04 
Hb 65/618 (10.5) 26/206 (12.6) 39/412 (9.5) 0.23 
Rhythm at start of ablation – n (%)    0.10 
Sinus rhythm 434 (68.6) 147 (70.3) 287 (67.7)  
AF 180 (28.4) 59 (28.2) 121 (28.5)  
AFL 12 (1.9) 0 12 (2.8)  
Pacing 7 (1.1) 3 (1.4) 4 (0.9)  
Type of ablation – n (%)    0.36 
PVI 571 (90.2) 192 (91.9) 379 (89.4)  
PVI plus other ablation 59 (9.3) 17 (8.1) 42 (9.9)  
Other ablation without PVI 3 (0.5) 0 3 (0.7)  
Ablation energy source – n (%)    0.46 
Radiofrequency 402 (63.5) 126 (60.3) 276 (65.1)  
Cryoablation 186 (29.4) 68 (32.5) 118 (27.8)  
Other 45 (7.1) 15 (7.2) 30 (7.1)  
Procedure duration (min) – median (q1, q3) 135 (110, 175) 134 (104-165) 138 (110, 180) 0.06 
Vascular access complication† 3 (0.5) 2 (1.0) 1 (0.2) 0.21 
Nights spent in hospital after ablation     
Median (q1, q3) 1 (1, 2) 1 (1, 2) 1 (1, 2) 0.003 
Mean (SD) 1.7 (1.7) 2.1 (2.3) 1.6 (1.3) 0.004 
*Number of patients with available information is given since some patients had missing values 
†Defined as leading to prolongation of in-hospital stay or specific therapy such as surgery or 
supplementation of coagulant factors. 









Table 3. Outcomes 







Primary outcome*     
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Primary endpoint: composite all-cause 
death, stroke or major bleeding 
45 (7.1%) 19 (9.1%) 26 (6.1%) 0.19 
Death 2 (0.3%) 1 (0.5%) 1 (0.2%) 0.61 
Stroke or TIA 2 (0.3%) 0  2 (0.5%) 0.32 
Major bleeding (BARC 2-5) 42 (6.6%) 19 (9.1%) 23 (5.4%) 0.09 
BARC 2: bleeding requiring 
medical attention 
21 (3.3%) 12 (5.7%) 9 (2.1%) 0.03 
BARC 3a: haemoglobin drop of 
30 to< 50 g/L or requiring 
transfusion 
9 (1.4%) 3 (1.4%) 6 (1.4%) 0.98 
BARC 3b: haemoglobin drop >50 
g/L, or requiring surgery or iv 
vasoactive agents, or cardiac 
tamponade 
11 (1.7%) 3 (1.4%) 8 (1.9%) 0.68 
BARC 3c: intracranial 
haemorrhage 
1 (0.2%) 1 (0.5%) 0 0.15 
TIMI major bleeding (intracranial bleed, 
or bleeding resulting in haemoglobin 
drop of ≥50 g/L, or bleeding resulting in 
death within 7 days) 
4 (0.6%) 2 (1.0%) 2 (0.5%) 0.47 
ISTH major bleeding 24 (3.8%) 11 (5.3%) 13 (3.1%) 0.19 
Cardiac tamponade 7 (1.1%) 2 (1.0%) 5 (1.2%) 0.80 
Secondary outcomes     
Cardiovascular hospitalization - n (%) 136 (21.5%) 53 (25.4%) 83 (19.6%) 0.10 
Nights spent in hospital during follow-








Recurrent AF 185/619 (29.9) 71/207 (34.3) 114/412 (27.7) 0.09 
One time 69 (11.1) 27 (13.0) 42 (10.2)  
Several times 87 (14.1) 35 (16.9) 52 (12.6)  
Still in AF 29 (4.7) 9 (4.4) 20 (4.9)  
*Shown are number of patients per group. Some patients had more than one event. 
Number of patients with available information is given when patients had missing values 
AF, atrial fibrillation; BARC, Bleeding Academic Research Consortium; ISTH, International Society on Thrombosis and 


















Table 4. Quality of life   
 All patients  Women Men P-value* 
SF-12 physical component     
Baseline 44.6 (37.7, 51.4) 42.2 (36.3, 48.6) 45.5 (39.2, 52.9) <0.001 
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n=597 n=196 n=401 
Follow up 48.6 (42.0, 54.2) 
n=564 
45.6 (39.8, 51.3) 
n=190 
50.8 (43.2, 55.0) 
n=374 
<0.001 
Change     
Absolute – median (q1, q3) 2.5 (-2.1, 8.1) 2.1 (-3.5, 8.4) 2.7 (-1.3, 8.0) 0.26 
Percentage – median (q1, q3) 5.6 (-4.0, 20) 
n=547 
5.1 (-6.9, 20.9) 
n=184 
5.9 (-3.2, 19.1) 
n=363 
 
P-value†  <0.001 0.001 <0.001  
SF-12 mental component     
Baseline 50.3 (42.7, 57.5) 
n=598 
48.2 (40.6, 55.2) 
n=197 
51.8 (43.6, 58.0) 
n=401 
<0.001 
Follow up 54.4 (46.0, 58.6) 
n=565 
52.9 (45.2, 57.5) 
n=191 
54.9 (47.3, 59.7) 
n=374 
0.01 
Change     
Absolute – median (q1, q3) 1.2 (-3.2, 8.0) 1.8 (-3.2, 8.7) 0.4 (-3.3, 7.7) 0.17 
Percentage – median (q1, q3) 2.0 (-6.6, 17.3) 
n=548 
3.7 (-6.1, 19.1) 
n=185 
1.6 (-6.6, 16.3) 
n=363 
 
P-value† <0.001 <0.001 0.002  
Karnofsky scale     
Baseline 90 (80, 90) 
n=633 
80 (80, 90) 
n=209 
90 (80, 90) 
n=424 
0.04 
Follow up 100 (90, 100) 
n=619 
100 (90, 100) 
n=207 
100 (90, 100) 
n=412 
0.06 
Change     
Absolute – median (q1, q3) 10 (0, 10) 0 (0, 10) 10 (0, 10) 0.60 
Percentage – median (q1, q3) 
 
11.1 (0.0, 12.5) 
n=619 
0 (0, 12.5) 
n=207 
11.1 (0.0, 12,5) 
n=412  
P-value† <0.001 <0.001 <0.001  
EQ-5D score     
Baseline 0.80 (0.69, 1.00) 
n=598 
0.76 (0.69, 0.88) 
n=198 
0.80 (0.73, 1.00) 
n=400 
<0.001 
Follow up 0.85 (0.73, 1.00) 
n=565 
0.80 (0.69, 1.00) 
n=188 
0.85 (0.76, 1.00) 
n=377 
<0.001 
Change     
Absolute – median (q1, q3) 0.00 (-0.04, 0.14) 0.00 (-0.07, 0.12) 0.00 (0.00, 0.15) 0.09 
Percentage – median (q1, q3) 
 
0.0 (-5.0, 17.6) 
n=547 
0.0 (-11.7, 17.3)  
n=183 
0.0 (0.0, 17.6) 
 n=364  
P-value† <0.001 0.27 <0.001  
All values are depicted as median (q1, q3). In all cells the number (n) of patients with available data is shown. 
*P-value women versus men 
†P-value between baseline and end of follow-up measurements 







Table 5. Cognitive function  
 All patients  Women Men P-value* 
MoCA score     
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Baseline 27 (25, 29) 
n=618 
27 (24, 29) 
n=206 
27 (25, 29) 
n=412 
0.54 
Follow up 28 (26, 29) 
n=607 
28 (26, 29) 
n=204 
28 (26, 29) 
n=403 
0.57 
Change     
Absolute – median (q1, q3) 1 (-1, 2) 1 (-1, 2) 0 (-1, 2) 0.37 
Percentage – median (q1, q3) 3.4 (-3.4, 7.7)  3.4 (-3.3, 8.2)  0 (-3.4, 7.4)   
 n=597 n=201 n=396  
P-value† <0.001 <0.001 <0.001  
At least mild cognitive 
impairment (MoCA <26)  
    














P-value <0.001 <0.001 <0.001  
MoCA scores are depicted as median (q1, q3), mild cognitive impairment as number (percentage). In all cells 
the number (n) of patients with available data is shown. 
*P-value women versus men 
†P-value between baseline and end of follow-up measurements 




Table 6. Acute brain lesions (MRI substudy) 







No. of lesions observed – n (%)    0.56 
No lesion 239 (74.0) 76 (71.7) 163 (75.1)  
Exactly one lesion 46 (14.2) 14 (13.2) 32 (14.7)  
Exactly two lesions 21 (6.5) 8 (7.5) 13 (6.0)  
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